After a breast cancer diagnosis, patients may come across terms such as HER2-positive, HER2-negative or HER2-low in their pathology reports.
These terms describe the presence or expression of a specific protein associated with cancer cell growth.
HER2 testing is an important part of breast cancer evaluation because it can influence treatment decisions.
What Is HER2?
HER2 stands for Human Epidermal Growth Factor Receptor 2.
It is a protein that helps regulate cell growth and division.
In certain cancers, particularly some breast cancers, tumour cells produce excessive amounts of HER2 protein or have extra copies of the HER2 gene.
This can contribute to faster tumour growth.
What Does HER2 Positive Mean?
HER2-positive cancer means that the tumour shows increased HER2 activity, generally due to HER2 protein overexpression or gene amplification.
HER2-positive breast cancers may grow more aggressively than some HER2-negative cancers. However, several effective HER2-targeted treatments are now available.
How Is HER2 Testing Performed?
HER2 testing is usually conducted on tumour tissue using:
1. Immunohistochemistry (IHC)
This test examines the amount of HER2 protein present on tumour cells.
Results are generally reported as:
- IHC 0.
- IHC 1+.
- IHC 2+.
- IHC 3+.
An IHC 2+ result is generally considered equivocal and usually requires additional testing.
2. In Situ Hybridisation (ISH)
ISH evaluates whether the tumour cells have increased copies of the HER2 gene.
It may be recommended to clarify equivocal IHC results.
What Are the Treatment Options for HER2-Positive Breast Cancer?
Treatment depends on the stage of cancer and individual patient factors.
Options may include:
- HER2-targeted medicines such as trastuzumab.
- Pertuzumab in eligible treatment settings.
- Antibody-drug conjugates such as trastuzumab emtansine or trastuzumab deruxtecan in appropriate indications.
- Chemotherapy.
- Surgery.
- Radiation therapy.
Some patients may receive a combination of chemotherapy and HER2-targeted treatment.
What Is HER2-Low Breast Cancer?
HER2-low generally refers to tumours that show IHC 1+ or IHC 2+ with negative ISH results.
This classification is important because certain antibody-drug conjugates may be considered for eligible patients in specific clinical settings.
HER2-low is not the same as HER2-positive disease.
Does HER2-Positive Mean Cancer Cannot Be Treated?
Absolutely not.
HER2-positive breast cancer has several established treatment options. Many patients benefit from HER2-targeted medicines, although individual outcomes vary.
Consult a Medical Oncologist in Raipur
HER2 status plays an important role in selecting appropriate breast cancer treatment.
Dr. Ayush Dubey, Medical Oncologist in Raipur, provides guidance on understanding pathology reports, HER2 testing and available treatment approaches.
Knowing the HER2 status of a tumour can help doctors choose more specific and effective treatment strategies.